SOUTH PLAINFIELD, N.J.
Feb. 12, 2014
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the pricing of an underwritten public offering of 4,489,796 million shares of common stock at a public offering price of
per share, before underwriting discounts. All of the shares in the offering are being offered by PTC. In addition, PTC has granted the underwriters an option for a period of 30 days to purchase up to 673,469 additional shares of common stock at the public offering price, less the underwriting discount.
J.P. Morgan and Credit Suisse are acting as joint lead book-running managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on
February 12, 2014
The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York
11717; telephone: 866-803-9204; or Credit Suisse Securities (
) LLC, Attn: Prospectus Department, One Madison Avenue,
New York, NY
10010; telephone: 800-221-1037; email:
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About PTC Therapeutics, Inc.
PTC is biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and form the basis for collaborations with leading biopharmaceutical companies.